Search results
Showing 501 to 550 of 2052 results for work
Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.
We assess the value of digital health technologies that offer the greatest potential to improve health and wellbeing.
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
Evidence-based recommendations on cryotherapy for chronic rhinitis. This involves destroying a nerve in the nose to reduce chronic rhinitis symptoms.
View recommendations for HTG692Show all sections
to feel emotions. They can also get: : Tolerance - the medicine does not work as well as it did at first. You need higher doses to get...
a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Support a quality standard...
a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Support a quality standard...
This quality standard covers referral and assessment for intermediate care and how to deliver the service. It covers bed-based intermediate care, crisis response, home-based intermediate care and reablement. It describes high-quality care in priority areas for improvement. It does not cover rehabilitation for specific conditions.
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.
Membership details, terms of reference, future meeting dates and past meeting minutes for our indicator advisory committee.
Membership details, terms of reference, future meeting dates and past meeting minutes for our indicator advisory committee.
"item":{"name":"In-depth"}}]} In-depth Our in-depth articles explore how our work is making a real difference to people's lives. Through...
Our indicators measure outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
NICE's business plan, annual report, charter, transformation story, gender pay gap report, framework agreement and other publications.
Information and links to key resources that will help you keep your practice up-to-date.
How to register with us as a medical technologies stakeholder.
Evidence-based recommendations on mini-incision surgery for total knee replacement. This involves using specially designed instruments to replace the knee using a smaller incision.
View recommendations for HTG220Show all sections
Sections for HTG220
How to register with us as a medical technologies stakeholder.
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 07 May 2026
Membership details, terms of reference and future meeting dates for our quality standards advisory committee.
Membership details, terms of reference and future meeting dates for our quality standards advisory committee.
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406
In development Reference number: GID-TA11341 Expected publication date: 02 December 2026
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.
This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS8Show all sections
Sections for QS8
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: Discussing treatment options
- Quality statement 3: Preventing relapse
- Quality statement 4: Stopping antidepressants
- Quality statement 5: Access to services for adults from minority ethnic backgrounds
- Update information
- About this quality standard
Healthy start vitamins: special report on cost effectiveness (ECD5)
This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering
a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Support a quality standard...
a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Support a quality standard...
This guideline covers routine preoperative tests for people aged over 16 who are having elective surgery. It aims to reduce unnecessary testing by advising which tests to offer people before minor, intermediate and major or complex surgery, taking into account specific comorbidities (cardiovascular, renal and respiratory conditions and diabetes and obesity). It does not cover pregnant women or people having cardiothoracic procedures or neurosurgery.
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
How NICE uses cookies and how you can manage them.
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
Agenda and papers of the NICE public board meeting on 17 May 2023
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on electrotherapy for treating grade I to III haemorrhoids in adults. This involves using electric current to shrink the haemorrhoids.
Managing medicines for adults receiving social care in the community (NG67)
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.
We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.
Interim process and methods statement for bringing together NICE guidance (PMG47)
This interim process and methods statement sets out the general principles guiding NICE's approach to including NICE technology appraisal recommendations in guideline topic areas. It also describes what the key changes are to existing methods and processes
PLGF-based testing to help diagnose suspected preterm pre-eclampsia (HTG630)
Evidence-based recommendations on placental growth factor (PLGF)-based testing to help diagnose suspected preterm pre-eclampsia. The tests are: DELFIA Xpress PLGF 1-2-3, DELFIA Xpress sFlt-1/PLGF 1-2-3 ratio, Elecsys immunoassay sFlt-1/PLGF ratio, Triage PLGF Test.
Repetitive transcranial magnetic stimulation for depression (HTG396)
Evidence-based recommendations on repetitive transcranial magnetic stimulation for depression. This involves placing an electromagnetic coil against the scalp, which creates electric currents in certain parts of the brain.
Good practice guidance – Integrated process statement (PMG12)
This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Agenda and papers of the NICE public board meeting on 22 July
How to register with us as a diagnostic technologies stakeholder.